NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced the appointment of Michael W. Heslop to the position of Vice President, International.
“Mike brings extensive pharmaceutical and biotechnology industry experience and a successful track record with global business and marketing strategy development,” said Don Kiepert, President and CEO, Lantheus Medical Imaging. “His appointment as Vice President, International aligns with our international business growth strategy. We look forward to expanding our global footprint, which will lead to improvement in the treatment of human disease.”
As Vice President, International, Mr. Heslop will lead all aspects of Lantheus’ international business. He will report to Cyrille Villeneuve, Chief Commercial Officer of Lantheus.
Mr. Heslop joins Lantheus with more than 25 years of general management and commercial experience, including his work with Glaxo Wellcome USA, Scriptgen Pharmaceuticals, and most recently Genzyme Corporation, where he was General Manager and Senior Vice President, Biosurgical Specialties. While at Genzyme, Mr. Heslop also held the positions of General Manager and Senior Vice President, Endocrinology, and Vice President, Global Marketing, PGH Business. Mr. Heslop received a B.S. degree in Biology from McGill University and an M.B.A. from Concordia University.
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The Company’s proven success in the field of diagnostic imaging provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, ABLAVAR® (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechneLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has approximately 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.